The University of North Carolina at Chapel Hill (UNC-CH) has enrolled approximately 65 treatment cases (including 10-15 minority accruals/year) plus 50-120 companion studies annually for the past four years. Our affiliate network is responsible for another 78-99 treatment accruals/year while maintaining excellent data quality control. UNC has broad leadership participation in the Group in Breast, Cancer Prevention and Control, GI, Lymphoma, Molecular Pathology, Pharmaceutics and Experimental Therapeutics, Radiation Oncology and Transplant, and is the research base for a UNC based Minority Initiative Program and a VCU based Minority CCOP. During the past five years, UNC has had four committee chairs, eight committee vice-chairs, seven administrative committee members, 14 modality committee members or modality committee liaisons, 14 scientific committee members or scientific committee liaisons, two Executive Committee members, two members of the Board of Directors, and seven protocol principal investigators. Members from UNC and its affiliates have chaired more than 35 studies and contributed to over 130 manuscripts and abstracts. Faculty at UNC-CH have expanded our commitment and Group leadership in the Breast, Surgery, GU, GI, Lymphoma, Solid Tumor Correlative Sciences, Thoracic, and PET committees (L. Carey, C. Dees, L. Dressler, R. Goldberg, H McLeod, B. O'Neil, R. Pruthi, C. Sartor, T. Shea, and M. Socinski). The addition of Drs. Goldberg (Chair, GI Committee), Howard McLeod (Vice Chair, PET Committee), and Charles Perou (Vice Chair, Breast Committee), have significantly enhanced our role in the Group. We therefore believe that this renewal application reflects the growing and crucial contribution that UNC-CH investigators provide to the Group in leadership, science, and service as well as our continued efforts to increase accrual both at UNC-CH and through affiliate members while maintaining rigorous control of quality data submission.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Program Officer
Mooney, Margaret M
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of North Carolina Chapel Hill
Internal Medicine/Medicine
Schools of Medicine
Chapel Hill
United States
Zip Code
Morrison, Vicki A; McCall, Linda; Muss, Hyman B et al. (2018) The impact of actual body weight-based chemotherapy dosing and body size on adverse events and outcome in older patients with breast cancer: Results from Cancer and Leukemia Group B (CALGB) trial 49907 (Alliance A151436). J Geriatr Oncol 9:228-234
Li, Megan; Mulkey, Flora; Jiang, Chen et al. (2018) Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance). Clin Cancer Res 24:4734-4744
Campbell, Jeffrey I; Yau, Christina; Krass, Polina et al. (2017) Comparison of residual cancer burden, American Joint Committee on Cancer staging and pathologic complete response in breast cancer after neoadjuvant chemotherapy: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 165:181-191
Giuliano, Armando E; Ballman, Karla V; McCall, Linda et al. (2017) Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918-926
Mandelblatt, Jeanne S; Cai, Ling; Luta, George et al. (2017) Frailty and long-term mortality of older breast cancer patients: CALGB 369901 (Alliance). Breast Cancer Res Treat 164:107-117
Freedman, Rachel A; Foster, Jared C; Seisler, Drew K et al. (2017) Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol 35:421-431
Himelstein, Andrew L; Foster, Jared C; Khatcheressian, James L et al. (2017) Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA 317:48-58
Kimmick, Gretchen G; Major, Brittny; Clapp, Jonathan et al. (2017) Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503). Breast Cancer Res Treat 163:391-398
Holstein, Sarah A; Jung, Sin-Ho; Richardson, Paul G et al. (2017) Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol 4:e431-e442
Basch, Ethan; Dueck, Amylou C; Rogak, Lauren J et al. (2017) Feasibility Assessment of Patient Reporting of Symptomatic Adverse Events in Multicenter Cancer Clinical Trials. JAMA Oncol 3:1043-1050

Showing the most recent 10 out of 149 publications